^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Leclaza (lazertinib)

    i
    Other names: GNS-1480, YH25448, GNS 1480, YH-25448, YH 25448, JNJ-73841937
    Company:
    J&J, Oscotec, Yuhan Corp
    Drug class:
    EGFR inhibitor
    Related drugs:
    11d
    Subcutaneous amivantamab vs intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Primary results, including overall survival (OS), from the global, phase 3, randomized controlled PALOMA-3 trial. (ASCO 2024)
    P3 | "Clinical Trial Registration Number: NCT05388669"
    Combination therapy • Late-breaking abstract • P3 data • Clinical
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation
    |
    Leclaza (lazertinib) • amivantamab SC (Ami-LC)
    11d
    Amivantamab plus lazertinib vs osimertinib in first-line EGFR-mutant advanced non-small cell lung cancer (NSCLC) with biomarkers of high-risk disease: A secondary analysis from the phase 3 MARIPOSA study. (ASCO 2024)
    P3 | "Clinical Trial Registration Number: NCT04487080"
    P3 data • Clinical
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation
    |
    Tagrisso (osimertinib) • Rybrevant (amivantamab-vmjw) • Leclaza (lazertinib)
    11d
    COCOON: Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib (clinicaltrials.gov)
    P2, N=300, Recruiting, Janssen Research & Development, LLC | N=180 --> 300
    Enrollment change • Adverse events • Metastases
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR L858R • EGFR exon 19 deletion
    |
    Rybrevant (amivantamab-vmjw) • Leclaza (lazertinib) • minocycline
    12d
    Premedication to Reduce Amivantamab Associated Infusion Related Reactions (clinicaltrials.gov)
    P2, N=74, Active, not recruiting, Janssen Research & Development, LLC | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion
    |
    Tagrisso (osimertinib) • Rybrevant (amivantamab-vmjw) • dexamethasone • Leclaza (lazertinib)
    18d
    MARIPOSA: Can Amivantamab and Lazertinib Replace Osimertinib in the Front-Line Setting? (PubMed, Lung Cancer (Auckl))
    The MARIPOSA trial was designed to study if the combination of amivantamab plus lazertinib in untreated epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) patients would provide improved progression-free survival. Here, we discuss the rationale for the study and the early results of MARIPOSA.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    EGFR mutation
    |
    Tagrisso (osimertinib) • Rybrevant (amivantamab-vmjw) • Leclaza (lazertinib)
    1m
    A Real-World Study of Patient Characteristics and Clinical Outcomes in EGFR Mutated Lung Cancer Treated with First-Line Osimertinib: Expanding the FLAURA Trial Results into Routine Clinical Practice. (PubMed, Cancers (Basel))
    Our data support the use of osimertinib in real-word settings and highlight the need for designing registration trials that are more inclusive of patient/disease characteristics seen in routine clinical practice. It is yet to be determined if the use of evolving first-line EGFR inhibitor combination strategies (either platinum-doublet chemotherapy plus osimertinib or amivantamab plus lazertinib) will similarly translate from clinical trials to real-word settings.
    Clinical data • Journal • Real-world evidence • Real-world
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation
    |
    Tagrisso (osimertinib) • Rybrevant (amivantamab-vmjw) • Leclaza (lazertinib)
    1m
    PALOMA: A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid Malignancies (clinicaltrials.gov)
    P1, N=166, Recruiting, Janssen Research & Development, LLC | Trial primary completion date: Jan 2024 --> Oct 2024
    Trial primary completion date • Metastases
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    EGFR exon 20 insertion • EGFR exon 20 mutation
    |
    Leclaza (lazertinib) • amivantamab SC (Ami-LC)
    1m
    CHRYSALIS: Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=751, Active, not recruiting, Janssen Research & Development, LLC | Trial completion date: Dec 2024 --> Jun 2025
    Trial completion date • Metastases
    |
    ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • MET amplification • EGFR exon 20 insertion • EGFR wild-type • MET exon 14 mutation • EGFR C797S • MET mutation • MET expression • EGFR exon 20 mutation • EGFR positive
    |
    carboplatin • pemetrexed • Rybrevant (amivantamab-vmjw) • Leclaza (lazertinib)
    2ms
    Lazertinib as a frontline treatment in patients with EGFR-mutated advanced non-small cell lung cancer: Long-term follow-up results from LASER201. (PubMed, Lung Cancer)
    This analysis demonstrated long-term clinical benefit with lazertinib 240 mg in patients with EGFR-mutated NSCLC who had not previously received EGFR TKIs. The safety profile for lazertinib was tolerable and consistent with that previously reported.
    Journal • Metastases
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR G719X
    |
    Leclaza (lazertinib)
    2ms
    Premedication to Reduce Amivantamab Associated Infusion Related Reactions (clinicaltrials.gov)
    P2, N=67, Recruiting, Janssen Research & Development, LLC | Trial completion date: Dec 2025 --> Aug 2026
    Trial completion date
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion
    |
    Tagrisso (osimertinib) • Rybrevant (amivantamab-vmjw) • dexamethasone • Leclaza (lazertinib)
    2ms
    COCOON: Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib (clinicaltrials.gov)
    P2, N=180, Recruiting, Janssen Research & Development, LLC | Not yet recruiting --> Recruiting
    Enrollment open
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR L858R • EGFR exon 19 deletion
    |
    Rybrevant (amivantamab-vmjw) • Leclaza (lazertinib) • minocycline
    3ms
    NeoLazer: Neoadjuvant Lazertinib With or Without Chemotherapy for Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=160, Not yet recruiting, Yonsei University
    New P2 trial
    |
    carboplatin • pemetrexed • Leclaza (lazertinib)
    3ms
    PALOMA: A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid Malignancies (clinicaltrials.gov)
    P1, N=166, Recruiting, Janssen Research & Development, LLC | Trial completion date: Feb 2025 --> Oct 2025
    Trial completion date • Metastases
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    EGFR exon 20 insertion • EGFR exon 20 mutation
    |
    Leclaza (lazertinib) • amivantamab SC (Ami-LC)
    3ms
    MARIPOSA-2: Is the treatment worse than the disease? (PubMed, Med)
    Passaro et al.1 demonstrated in EGFR+ NSCLC post-1L osimertinib both "quad" (lazertinib [L] + amivantamab [A] + chemotherapy [CP]) and "triplet" (ACP) regimens achieved improved median progression-free survival over CP. Nonetheless, a high incidence of adverse events requiring dose modifications may limit adaptation of the triplet and quad MARIPOSA-2 regimens.
    Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    Tagrisso (osimertinib) • Rybrevant (amivantamab-vmjw) • Leclaza (lazertinib)
    4ms
    PALOMA: A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid Malignancies (clinicaltrials.gov)
    P1, N=166, Recruiting, Janssen Research & Development, LLC | N=116 --> 166
    Enrollment change • Metastases
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    EGFR exon 20 insertion • EGFR exon 20 mutation
    |
    Leclaza (lazertinib) • amivantamab SC (Ami-LC)
    4ms
    Premedication to Reduce Amivantamab Associated Infusion Related Reactions (clinicaltrials.gov)
    P2, N=67, Recruiting, Janssen Research & Development, LLC | N=126 --> 67
    Enrollment change
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion
    |
    Tagrisso (osimertinib) • Rybrevant (amivantamab-vmjw) • dexamethasone • Leclaza (lazertinib)
    4ms
    PALOMA-3: A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=418, Active, not recruiting, Janssen Research & Development, LLC | Trial completion date: Oct 2024 --> Jan 2025
    Trial completion date • Metastases
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M
    |
    Tagrisso (osimertinib) • Leclaza (lazertinib) • amivantamab SC (Ami-LC)
    5ms
    A Study of Amivantamab and Lazertinib in People With Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P2, N=43, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Recruiting --> Active, not recruiting | Trial completion date: Jul 2024 --> Jul 2025 | Trial primary completion date: Jul 2024 --> Jul 2025
    Enrollment closed • Trial completion date • Trial primary completion date • Metastases
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation
    |
    Rybrevant (amivantamab-vmjw) • Leclaza (lazertinib)
    5ms
    COCOON: Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib (clinicaltrials.gov)
    P2, N=180, Not yet recruiting, Janssen Research & Development, LLC | Trial completion date: Nov 2026 --> Mar 2026
    Trial completion date • Adverse events • Metastases
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR L858R • EGFR exon 19 deletion
    |
    Rybrevant (amivantamab-vmjw) • Leclaza (lazertinib) • minocycline
    5ms
    Correspondence to: Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study. (PubMed, Ann Oncol)
    No abstract available
    P3 data • Journal • Metastases
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation
    |
    Tagrisso (osimertinib) • Rybrevant (amivantamab-vmjw) • Leclaza (lazertinib)
    5ms
    PALOMA: A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid Malignancies (clinicaltrials.gov)
    P1, N=116, Recruiting, Janssen Research & Development, LLC | Active, not recruiting --> Recruiting | Phase classification: P1b --> P1 | Trial completion date: Oct 2024 --> Feb 2025
    Enrollment open • Phase classification • Trial completion date • Metastases
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    EGFR exon 20 insertion • EGFR exon 20 mutation
    |
    Leclaza (lazertinib) • amivantamab SC (Ami-LC)
    5ms
    CHRYSALIS: Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=751, Active, not recruiting, Janssen Research & Development, LLC | Trial completion date: Jan 2024 --> Dec 2024
    Trial completion date • Metastases
    |
    ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • MET amplification • EGFR exon 20 insertion • EGFR wild-type • MET exon 14 mutation • EGFR C797S • MET mutation • MET expression • EGFR exon 20 mutation • EGFR positive
    |
    carboplatin • pemetrexed • Rybrevant (amivantamab-vmjw) • Leclaza (lazertinib)
    5ms
    MARIPOSA: A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=1074, Active, not recruiting, Janssen Research & Development, LLC | Trial completion date: Jul 2025 --> Jun 2027
    Trial completion date • Combination therapy • Metastases
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion
    |
    Tagrisso (osimertinib) • Rybrevant (amivantamab-vmjw) • Leclaza (lazertinib)
    5ms
    PALOMA-2: A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=390, Recruiting, Janssen Research & Development, LLC | Trial completion date: Nov 2025 --> Jul 2026
    Trial completion date • Metastases
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR exon 20 mutation
    |
    Tagrisso (osimertinib) • carboplatin • pemetrexed • Rybrevant (amivantamab-vmjw) • Leclaza (lazertinib) • amivantamab SC (Ami-LC)
    5ms
    A Randomized Phase II Study of LAZE rtiNib Alone Versus Lazertinib Plus bevaCizumab for NSCLC With EGFR + & Smoker (clinicaltrials.gov)
    P2, N=120, Recruiting, National Cancer Center, Korea
    New P2 trial
    |
    Avastin (bevacizumab) • Leclaza (lazertinib)
    5ms
    COCOON: Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib (clinicaltrials.gov)
    P2, N=180, Not yet recruiting, Janssen Research & Development, LLC | Trial completion date: Mar 2026 --> Nov 2026 | Trial primary completion date: Apr 2025 --> Jul 2025
    Trial completion date • Trial primary completion date • Adverse events • Metastases
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR L858R • EGFR exon 19 deletion
    |
    Rybrevant (amivantamab-vmjw) • Leclaza (lazertinib) • minocycline
    5ms
    Letter to the Editor regarding "Correspondence to: Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: Primary results from the phase III MARIPOSA-2 study" by Moik F, Riedl JM, and Ay C. (PubMed, Ann Oncol)
    No abstract available
    P3 data • Journal • Metastases
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation
    |
    Tagrisso (osimertinib) • Rybrevant (amivantamab-vmjw) • Leclaza (lazertinib)
    5ms
    Central Nervous System Outcomes of Lazertinib Versus Gefitinib in EGFR-Mutated Advanced NSCLC: A LASER301 Subset Analysis. (PubMed, J Thorac Oncol)
    In patients with CNS metastases, lazertinib significantly improved intracranial progression-free survival compared with gefitinib, with more durable responses.
    Journal • Metastases
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation
    |
    gefitinib • Leclaza (lazertinib)
    6ms
    PALOMA-2: A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=390, Recruiting, Janssen Research & Development, LLC | Trial completion date: Jan 2025 --> Nov 2025
    Trial completion date • Metastases
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR exon 20 mutation
    |
    Tagrisso (osimertinib) • carboplatin • pemetrexed • Rybrevant (amivantamab-vmjw) • Leclaza (lazertinib) • amivantamab SC (Ami-LC)
    6ms
    Lazertinib for NSCLC Harboring Activating EGFR Mutations in TKI naïve Patients (clinicaltrials.gov)
    P2, N=150, Recruiting, Myung-Ju Ahn | N=100 --> 150
    Enrollment change
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion
    |
    Leclaza (lazertinib)
    6ms
    CHRYSALIS: Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=751, Active, not recruiting, Janssen Research & Development, LLC | Recruiting --> Active, not recruiting
    Enrollment closed • Metastases
    |
    ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • MET amplification • EGFR exon 20 insertion • EGFR wild-type • MET exon 14 mutation • EGFR C797S • MET mutation • MET expression • EGFR exon 20 mutation • EGFR positive
    |
    carboplatin • pemetrexed • Rybrevant (amivantamab-vmjw) • Leclaza (lazertinib)
    6ms
    PALOMA: A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid Malignancies (clinicaltrials.gov)
    P1b, N=125, Active, not recruiting, Janssen Research & Development, LLC | Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2023 --> Jan 2024
    Enrollment closed • Trial primary completion date • Metastases
    |
    EGFR (Epidermal growth factor receptor) • MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    EGFR exon 20 insertion • EGFR exon 20 mutation
    |
    Leclaza (lazertinib) • amivantamab SC (Ami-LC)
    6ms
    A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=418, Active, not recruiting, Janssen Research & Development, LLC | Recruiting --> Active, not recruiting | Trial completion date: Feb 2024 --> Oct 2024
    Enrollment closed • Trial completion date • Metastases
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M
    |
    Tagrisso (osimertinib) • Leclaza (lazertinib) • amivantamab SC (Ami-LC)
    6ms
    COCOON: Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib (clinicaltrials.gov)
    P2, N=180, Not yet recruiting, Janssen Research & Development, LLC
    New P2 trial • Adverse events • Metastases
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR L858R • EGFR exon 19 deletion
    |
    Rybrevant (amivantamab-vmjw) • Leclaza (lazertinib) • minocycline
    6ms
    Lazertinib & Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib Treatment (clinicaltrials.gov)
    P2, N=47, Not yet recruiting, Samsung Medical Center
    New P2 trial
    |
    EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • MET amplification • EGFR C797S • EGFR mutation + MET-CEP7 fusion
    |
    Tepmetko (tepotinib) • Leclaza (lazertinib)
    6ms
    Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: Primary results from the phase 3 MARIPOSA-2 study. (PubMed, Ann Oncol)
    Amivantamab-chemotherapy and amivantamab-lazertinib-chemotherapy improved progression-free survival and intracranial progression-free survival versus chemotherapy in a population with limited options after disease progression on osimertinib. Longer follow-up is needed for the modified amivantamab-lazertinib-chemotherapy regimen.
    P3 data • Journal • Metastases
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion
    |
    Tagrisso (osimertinib) • carboplatin • pemetrexed • Rybrevant (amivantamab-vmjw) • Leclaza (lazertinib)
    6ms
    EGFR-Mutant NSCLC: Spotlight on Amivantamab. (PubMed, Cancer Discov)
    Amivantamab paired with chemotherapy is a superior first-line option for patients with exon 20-mutated disease. Beyond this subset, compared with standard osimertinib, the combination with or without lazertinib also boosted progression-free survival, albeit at the cost of added toxicity.
    Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation
    |
    Tagrisso (osimertinib) • Rybrevant (amivantamab-vmjw) • Leclaza (lazertinib)
    7ms
    Real-world clinical evidence of lazertinib use in acquired EGFR T790M mutated non-small cell lung cancer. (PubMed, Transl Lung Cancer Res)
    Our result demonstrates the real-world clinical efficacy of lazertinib in acquired EGFR T790M mutation. Although dose reduction due to adverse events was not uncommon, it did not impair clinical efficacy of lazertinib.
    Journal • Real-world evidence • Real-world
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR T790M
    |
    Leclaza (lazertinib)
    7ms
    CHRYSALIS-2: A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=460, Recruiting, Janssen Research & Development, LLC | Trial completion date: Oct 2027 --> Feb 2027
    Trial completion date • Combination therapy • Metastases
    |
    EGFR (Epidermal growth factor receptor) • MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR expression • MET expression • EGFR exon 20 mutation • EGFR expression + MET expression
    |
    Tagrisso (osimertinib) • carboplatin • pemetrexed • Rybrevant (amivantamab-vmjw) • Leclaza (lazertinib)